Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $220.03M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 5.46M
Average 3.33M
CABA Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Cabaletta Bio, Inc.NASDAQ: CABA
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets falls 10.3% from a year ago
Total assets stood at $148.15M at the end of Q1 FY2026, down 10.3% from a year earlier and down 10.3% from the prior quarter. Over 3 fiscal years it compounded at +12.2% a year.
Context
- Total assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total assets keeps falling in the next quarterly balance sheet after a -10.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 165.08M USD
- Year-over-year change
- -10.8%
- 4-year CAGR
- +6.9%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 165.08M | -10.8% |
| FY2024 | 2024-12-31 | 185.05M | -27.0% |
| FY2023 | 2023-12-31 | 253.65M | +116.9% |
| FY2022 | 2022-12-31 | 116.97M | -7.4% |
| FY2021 | 2021-12-31 | 126.34M | — |
Total Assets vs competitors
How CABA compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of -10.3% is the 4th highest of 11, against a peer median of -20.7%.
- Over three fiscal years its annual growth of +12.2% compares with a peer median of -15.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $395.96M USD | -22.1% | -20.3% | |
| Mar 2026 | $350.63M USD | -18.4% | -28.7% | |
| Mar 2026 | $326.28M USD | +112.2% | +92.2% | |
| Mar 2026 | $267.08M USD | -39.3% | -22.1% | |
| Mar 2026 | $257.02M USD | -1.4% | +63.7% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $250.36M USD | +99.2% | +40.4% |
| Mar 2026 | $149.34M USD | -43.4% | -28.7% | |
| Mar 2026 | $148.15M USD | -10.3% | +12.2% | |
| Dec 2025 | A$147.2M AUD | -19.3% | +15.4% | |
| Mar 2026 | $110.56M USD | -32.0% | -17.1% | |
| Mar 2026 | €99.14M EUR | -39.5% | -13.0% | |
| Peer median (excluding CABA) | — | -20.7% | -15.1% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 122.22M | 81.61M | 193.24M | 163.96M | 82.98M |
| Short-term Investments | 0 | 24.94M | 48.01M | 0 | 50.62M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.97M | 2.29M | 0 | 2.71M | 5.27M |
| Total Current Assets | 124.54M | 108.83M | 244.49M | 166.68M | 138.87M |
| Property, Plant & Equipment (Net) | 1.44M | 7.57M | 7.45M | 16.08M | 21.05M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 357K | 565K | 1.71M | 6.23M | 5.16M |
| Total Non-current Assets | 1.8M | 8.13M | 9.16M | 22.31M | 26.21M |
| Total Assets | 126.34M | 116.97M | 253.65M | 185.05M | 165.08M |
| Account Payables | 2.33M | 2.46M | 4.55M | 4.92M | 6.64M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.07M | 1.33M | 40K | 8.36M | 9.8M |
| Total Current Liabilities | 8.38M | 9.49M | 15.99M | 27.09M | 50.15M |
| Long-term Debt | 0 | 0 | 0 | 0 | 2.88M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 2.96M | 1.46M | 5.63M | 2.88M |
| Total Liabilities | 8.38M | 12.45M | 17.45M | 32.71M | 53.03M |
| Common Stock | 0 | 0 | 0 | 1K | 1K |
| Retained Earnings | (112.59M) | (165.56M) | (233.24M) | (349.1M) | (516.96M) |
| Accumulated OCI | 0 | (47K) | 39K | 0 | 25K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 117.96M | 104.52M | 236.2M | 152.34M | 112.05M |
| Total Debt | 0 | 5.14M | 5.02M | 15.6M | 27.1M |
| Net Debt | (122.22M) | (76.47M) | (188.22M) | (148.36M) | (55.88M) |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.